IRONWOOD PHARMACEUTICALS, INC. Payments for Restructuring
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Payments for Restructuring of $19.81 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2023-12-31 was $3.52M.
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2023-09-30 was $5.14M.
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2021-12-31 was $486.00K.
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for the quarter ending 2021-09-30 was $1.07M.
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for fiscal 2025 was $19.81M, a 93.09% increase from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for fiscal 2024 was $10.26M, a 9.00% increase from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for fiscal 2023 was $9.41M.
- IRONWOOD PHARMACEUTICALS, INC. payments for restructuring for fiscal 2021 was $10.66M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2025-12-31 | $19.81M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $10.26M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $8.66M derived: sum of 2 quarters · filed 2025-03-31 | $9.41M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $5.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.89M 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $753.00K 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $486.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $1.55M derived: sum of 2 quarters · filed 2023-02-16 | $5.02M derived: sum of 3 quarters · filed 2023-02-16 | $10.66M 10-K · filed 2023-02-16 |
| 2021-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.54M derived: sum of 2 quarters · filed 2021-11-04 | $10.18M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $3.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $9.11M 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | $5.64M 10-Q · filed 2021-05-06 | |||
| 2018-03-31 | $1.07M 10-Q · filed 2018-05-04 | |||
| 2014-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $281.00K derived: sum of 2 quarters · filed 2015-02-18 | $1.36M derived: sum of 3 quarters · filed 2015-02-18 | $3.65M 10-K · filed 2015-02-18 |
| 2014-09-30 | $271.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $1.35M derived: sum of 2 quarters · filed 2014-11-05 | $3.64M 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $3.37M 10-Q · filed 2014-08-05 | ||
| 2014-03-31 | $2.29M 10-Q · filed 2014-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |